Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

Expert Discusses Recent CLL Approval

Friday, February 15, 2019

Suman Kambhampati, MD, the co-director of blood cancer research at Sarah Cannon Cancer Institute at HCA Midwest Health, discusses the recent FDA approval of ibrutinib (Imbruvica) plus obinutuzumab (Gazyva) for the frontline treatment of patients with chronic lymphocytic leukemia (CLL).

The approval was based on the phase III iLLUMINATE trial, which showed that ibrutinib plus obinutuzumab was the first non-chemotherapy combination that was extremely effective in treating nearly all subtypes of patients with CLL. The combination elicited a longer progression-free survival (PFS), nearly a 100% response rate, and better complete responses (CR) than treatment with ibrutinib alone, making it an extremely exciting treatment option for these patients.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.